Related Experiment Video
Updated: Dec 11, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
BRAF mutations in KIT/PDGFRA positive gastrointestinal stromal tumours (GISTs): Is their frequency underestimated?
Karin Jašek1, Barbora Váňová1, Marián Grendár1
1Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin (JFM CU), Biomedical Center Martin JFM CU, 036 01 Martin, Slovakia.
Abstract:
BRAF V600E mutations in GISTs are considered to be one of the mutational events in KIT/PDGFRA negative or positive GISTs, respectively. BRAF mutated GISTs usually do not respond to imatinib treatment, even more GISTs with imatinib sensitive KIT mutation. However, they are almost phenotypically and morphologically identical with KIT/PDGFRA positive GISTs. In general, due to the small number of BRAF mutations in GIST and because of the rarity of concomitant BRAF/KIT or BRAF/PDGFRA mutations, their frequency may be depreciated. The aim of this study was BRAF mutation detection in KIT/PDGFRA positive GISTs and their verification by other molecular methods. We applied the sensitive droplet digital PCR on 35 randomly selected KIT/PDGFRA positive GISTs to detect V600E mutations. We have established two criteria for the evaluation of samples: false positive rate (FPR) based on the negative controls; Limit of Detection (LoD) based on the serial dilution of positive control from RKO cell line harboring heterozygous V600E mutation in constant wild-type DNA background. Results from ddPCR were verified by other molecular methods: allele-specific PCR, dideoxysequencing, competitive allele-specific TaqMan PCR (castPCR). FPR was determined as 5 (∼4.4) positive droplets, and LoD was assessed to 3.4293 copies/μL what is the method sensitivity of 0.0162 %. We identified eight KIT/PDGFRA positive patients with concomitant V600E mutation. The five of them were in coexistence with KIT mutation and three with PDGFRA mutation. We also included the liver metastasis, but data from primary tumour were not available. We achieved the very high sensitivity of the ddPCR method for detecting BRAF mutation in GISTs to have importance from the point of view of therapy.
Insights
BRAF V600E mutations are found in some gastrointestinal stromal tumors (GISTs), even those with KIT/PDGFRA mutations. Detecting these BRAF mutations is crucial for treatment decisions, as they impact imatinib response.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- BRAF V600E mutations represent a distinct molecular event in gastrointestinal stromal tumors (GISTs).
- GISTs with BRAF mutations often exhibit resistance to imatinib therapy, posing a therapeutic challenge.
- Phenotypic and morphologic similarities between BRAF-mutated and KIT/PDGFRA-mutated GISTs can obscure diagnosis.
Purpose of the Study:
- To detect BRAF V600E mutations in KIT/PDGFRA-positive GISTs.
- To verify BRAF mutation findings using orthogonal molecular techniques.
- To assess the diagnostic utility of droplet digital PCR (ddPCR) for BRAF mutations in GIST.
Main Methods:
- Sensitive droplet digital PCR (ddPCR) was employed to detect BRAF V600E mutations in 35 KIT/PDGFRA-positive GIST samples.
- Method sensitivity was established through rigorous determination of false positive rate (FPR) and limit of detection (LoD).
- ddPCR results were validated using allele-specific PCR, dideoxysequencing, and competitive allele-specific TaqMan PCR (castPCR).
Main Results:
- The ddPCR method demonstrated high sensitivity, with an LoD of 3.4293 copies/μL (0.0162% sensitivity).
- Eight KIT/PDGFRA-positive GIST patients with concomitant BRAF V600E mutations were identified.
- Concomitant mutations included five cases with KIT and three cases with PDGFRA mutations.
Conclusions:
- Droplet digital PCR is a highly sensitive method for detecting BRAF V600E mutations in GISTs.
- The identification of concomitant BRAF mutations in KIT/PDGFRA-positive GISTs has significant therapeutic implications.
- Accurate BRAF mutation detection is essential for optimizing treatment strategies in GIST patients.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
10:16Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
Related Concept Videos
The Ras Gene
Ras is a...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation